News

SLIT: Guidelines in progress and practical concerns


 

AT 2015 AAAAI ANNUAL MEETING

References

“Physicians think that what’s most important for the patient is efficacy, cost, and side effects,” but patients’ ability to comply is also key, she said, and clinicians should let patient preference guide their decisions when possible.

Dr. Cox disclosed ongoing consulting relationships with Greer and Circassia. Dr. Larenas Linnemann disclosed financial support from AstraZeneca, Pfizer, Novartis, MEDA, Sanofi, and Senosiain.

Pages

Recommended Reading

FDA approves pediatric dosage of QNASL
MDedge Pediatrics
Guideline clarifies first-line treatment for allergic rhinitis
MDedge Pediatrics
Get the baby a dog: Infants’ gut biota seen to affect allergy risk
MDedge Pediatrics
Skin patch therapy for peanut allergy wins plaudits
MDedge Pediatrics
Breastfeeding-related changes in gut bacteria protect against childhood allergy
MDedge Pediatrics
Early consumption of peanuts can induce tolerance in high-risk children
MDedge Pediatrics
Reslizumab aces pivotal trials in asthma with eosinophilia
MDedge Pediatrics
Annual recurrence rate of anaphylaxis in kids is nearly 30%
MDedge Pediatrics
Epinephrine use for anaphylaxis in schools: First national survey
MDedge Pediatrics
Beware common management pitfalls in severe refractory pediatric AD
MDedge Pediatrics